Ocugen announces FDA has declined to issue Emergency Use Authorization for pediatric use of COVAXIN to prevent COVID-19 in individuals aged two to 18

Sample article from our Health Care Sector

March 7, 2022 (press release) –

Drug maker, Ocugen, Inc. (OCGN), said on Friday that the U.S. Food and Drug Administration or FDA, has declined to issue an Emergency Use Authorization or EUA, for the pediatric use of COVAXIN to prevent Covid-19.

However, the company said it "intends to continue working with FDA to evaluate the regulatory pathway for the pediatric use of COVAXIN."

Earlier, Ocugen had intended to get EUA for the vaccine to prevent Covid-19 caused by SARS-CoV-2 in the children of the age group of 2 to 18 years.

 

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

More from our Health Care Sector Coverage
See our dashboard in action - schedule an demo
Chelsey Quick
Chelsey Quick
- VP Client Success -

We offer built-to-order health care sector coverage for our clients. Contact us for a free consultation.

Sectors

Sectors

Channels

Channels

Consumer Markerts

Consumer Markets

Business Drivers

Business Drivers

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Latest Public Posts

Useful Links

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

contact@industryintel.com
www.industryintel.com

About Cookies On This Site

This website stores cookies on your computer. These cookies are used to improve your website experience and provide more personalized services to you, both on this website and through other media. To find out more about the cookies we use, see our Privacy Policy. We won't track your information when you visit our site. But in order to comply with your preferences, we'll have to use just one tiny cookie so that you're not asked to make this choice again.